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Abstract
The microtubule-associated protein tau, in a hyperphosphorylated form, aggregates into insoluble
paired-helical filaments (PHFs) in Alzheimer’s disease (AD) and other tauopathies. In AD, there are
approximately 8 mol of phosphate per mol of tau distributed among approximately 30 PHF
phosphorylation sites as compared to 2–3 phosphate per mol in normal brain. In AD, kinases such
as glycogen synthase kinase-3β (GSK-3β) are believed to be involved in generation of
hyperphosphorylated tau. However, the functional consequences of hyperphosphorylation on the
microtubule binding and polymerization of tau are not well understood. To address this question, we
have generated pseudo-hyperphosphorylation mutants consisting of six and seven sites in the proline
rich region and carboxy-terminus of tau by amino acid substitution. In addition, several single, double
and triple pseudo-phosphorylation mutants were also generated. Pseudo-phosphorylation of tau
decreases its affinity for microtubules, and pseudo-hyperphosphorylated forms of tau do not have
significantly decreased microtubule binding as compared to single and double-sites. Three pseudo-
hyperphosphorylated forms of tau with altered SDS-PAGE migration have a greater effect on its
inducer mediated polymerization, slowing the rate of nucleation and elongation. Based on the
observations that pseudo-hyperphosphorylated tau has decreased affinity for microtubules and
reduced inducer-initiated rates of nucleation and polymerization, we propose that this combination
could be the cause for the increased cytotoxicity of hyperphosphorylated tau in Alzheimer’s disease
and also explain the potentially beneficial role of tau polymerization and NFT formation.
Neurofibrillary tangles (NFTs) are a prominent hallmark of Alzheimer’s disease (AD) and
other related neurodegenerative disorders, such as frontotemporal dementia and Parkinsonism
linked to chromosome 17 (FTDP-17) (reviewed in (1)). Although the role of NFTs in
Alzheimer’s disease is not clear, the location and amount of NFTs directly correlate with the
type and severity of cognitive impairment (2,3). NFTs contain large amounts of abnormal
protein deposits in the form of straight and paired-helical filaments (4,5) that are composed
almost entirely of the microtubule-associated protein tau (6–9) in a hyperphosphorylated state
(6). Tau protein is a soluble protein that normally functions to promote the assembly and
stabilization of the microtubule cytoskeleton (10), and phosphorylation of tau is known to alter
its functions (reviewed in (11)). However, it is still unclear how tau hyperphosphorylation is
linked to its aggregation and neuronal degeneration observed in these diseases.
At least 30 phosphorylation sites in PHF tau, about half of which are proline-directed sites,
have been identified by mass spectrometry and phospho-amino acid analysis or by
phosphorylation-specific monoclonal antibodies. (reviewed in (11,12)). The kinase(s)
responsible for the hyperphosphorylation of tau in AD is not clear. It has been suggested that
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more than one combination of kinases and/or phospatases might be involved in converting
normal tau to hyperphosphorylated tau (13). The proline-directed kinase GSK-3β is believed
to be involved in this process since it phosphorylates tau at many of the same sites that are
found to be phosphorylated in paired helical filaments of AD (14–17), and active GSK-3β is
associated with the development of NFTs in AD (18). According to our previous observations,
GSK-3β phosphorylates soluble and polymerized tau at a minimum of eleven and five sites
respectively (19,20). Phosphorylation at these sites does not change the amount of tau
polymerization, but is sufficient to cause tau filaments to coalesce into tangle-like aggregates
similar to those isolated from Alzheimer’s disease brain (19,20).
Due to the number and proximity of tau phosphorylation, in combination with the relative
promiscuity with which most kinases act upon tau, the use of kinases to investigate the effects
of specific sites on the function of tau is virtually impossible. It is therefore common for these
investigations to employ site-directed mutagenesis to generate pseudo-phosphorylation
variants of tau (21–28), although this approach is unlikely to completely mimic
phosphorylative changes. We previously showed that the amino acid substitution of glutamic
acid for serines or threonines to generate pseudo-phosphorylation mutations at S202 and T205
resulted in only subtle effects on the polymerization characteristics and microtubule binding
of tau (28). However, it is not known whether adding additional pseudo-phosphorylation sites
that are normally phosphorylated by GSK-3β to generate a “pseudo-hyperphosphorylation”
version of tau has a greater effect on its function. To address this question, we have generated
pseudo-hyperphosphorylated variants with six (6-phos) and seven (7-phos) pseudo-
phosphorylation changes. The sites chosen for investigation include the five sites that are
phosphorylated by GSK-3β when tau is in a polymerized state (S199, T205, T231, S396 and
S404) (20). 6-phos also included pseudo-phosphorylation at S202. S202 was added to the core
five sites since the AT8 antibody recognizes phosphorylation of tau at both S199 and S202
(29), and antibodies to S202 alone were not available for our previous study of GSK3β
phosphorylation of tau. Similarly, S235, which is recognized in combination with T231 by the
TG-3 antibody (30), was added to 6-phos to generate a 7-phos mutant. Single, double and triple
pseudo-phosphorylation mutants were also investigated to control for the possibility that fewer
sites could have similar effects to the pseudo-hyperphosphorylated versions of tau. In addition
to S199, S202, T205, T231, S235, S396 and S404, other sites were also investigated. T212E
was included since it has previously be shown to promote the in vitro assembly of tau to a high
level (26). S208D, S210D and S208/210D were also included. These sites are not
phosphorylated by GSK-3β, but are in the same proline-rich region of tau that the majority of
GSK-3β phosphorylation sites are found. They are known to be phosphorylated by tau-tubulin
kinase (TTK) (31) and are also phosphorylated in PHF tau (32). The pseudo-phosphorylation
mutants were assayed for changes in SDS-PAGE migration, microtubule binding and
arachidonic acid-induced polymerization. We have made two key observations: most pseudo-
phosphorylation and pseudo-hyperphosphorylation variants decrease the microtubule binding
of tau in a fashion similar to GSK-3β phosphorylated tau, and kinetic analyses of
polymerization indicate that pseudo-hyperphosphorylated tau mimics with AD-like changes
in SDS-PAGE electrophoretic mobility have increased lag times and reduced apparent rates
of elongation compared to single or paired mimics. These results suggest a possible mechanism
for the increased toxicity of hyperphosphorylated tau in vivo.
Materials and Methods
Chemicals and Reagents
Arachidonic acid was obtained from Cayman Chemicals (Ann Arbor, MI), IPTG from
Calbiochem (EMD Biosciences, La Jolla, CA), SDS-PAGE protein marker from Invitrogen
(Gaithersburg, MD), urea from Bio-Rad (Hercules, CA), and uranyl acetate and formvar carbon
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coated grids from Electron Microscopy Sciences (Hatfield, PA). Wild-type, P301L and pseudo-
phosphorylation mutant tau protein (441 amino acids) were expressed and purified as described
previously (28). Pseudo-phosphorylation mutants were generated using the QuikChange site-
directed mutagenesis kit from Stratagene (La Jolla, CA). S/T to E mutants and S/T to D mutants
were generated at amino acids S199 and T231. S199E was found to have indistinguishable
polymerization characteristics as S199D (not shown). T231E and T231D were also
indistinguishable in their polymerization (not shown). Protein concentration was determined
by a commercial BCA assay from Pierce Chemical (Rockford, IL) using bovine serum albumin
(Pierce Chemical, Rockford, IL) as a standard.
SDS-PAGE and SDS-PAGE with urea
Protein samples (1 μg per lane) were boiled for 5 min in sample buffer containing 2% SDS
and 1% beta-mercapto-ethanol, fractionated on 15% SDS-PAGE and stained with Coomassie
brilliant blue (33). For denaturing SDS-PAGE, protein samples (1 μg per lane) were boiled for
5 min in sample buffer containing 2% SDS and 1% beta-mercapto-ethanol and 6 M urea.
Samples were fractionated on 15% SDS-PAGE with 6 M urea and stained with Coomassie
brilliant blue (33).
Kinetics of ARA induced polymerization
2 μM tau protein (wild-type and pseudo-phosphorylation tau mutants) was incubated in
polymerization buffer (10 mM HEPES pH 7.64, 100 mM NaCl, 0.1 mM EDTA and 5 mM
DTT) at room temperature in the presence of 75 μM arachidonic acid (ARA) (in ethanol, final
concentration: 3.75%) in the 5 × 5 mm optical glass fluorometer cuvettes (Starna Cells,
Atascadero, CA) (34). The amount of polymerization was monitored by LLS at regular
intervals for 20 hr with 5 mW solid state laser (λ= 475 nm, B & W Tek, Inc., Newark, DE).
Images were captured at a right angle to the incident light using a SONY XC-ST270 digital
camera. Captured images were imported into Adobe Photoshop 7.0.1 and the intensity of the
scattered light was measured as described previously (28). The pictures were captured at an
aperture of f5.6–8 or f8 and then normalized to the intensity corresponded to the exposure at
f5.6–8. The data were fit to a non-linear Gompertz function:
where y is the value of laser light scattering measured at time t; a is the maximum amount of
light scattering; ti is the point of inflection where the increase in scattering is at its maximum;
and b is equal to 1/kapp. kapp is proportional to the rate of polymerization (26). The lag time
for polymerization, or the amount of time required to observe significant amounts of
polymerization, was calculated using the formula: ti − b (26). The Gompertz function has been
used as a model for growth curves (35), including as a model for tau polymerization (26). Errors
in the kinetics parameters were assessed by individually fitting three separate kinetics
experiments to the Gompertz function to obtain three independent measures of LLSmax, kapp
and lag times. These values were averaged and reported ± standard deviation.
Transmission electron microscopy
Tau polymerization reactions were diluted 10-fold with polymerization buffer then fixed with
glutaraldehyde (2% final concentration) for 5 min. Ten microliters of fixed reactions were
placed on formvar-carbon coated grids (1 min), washed with water, blotted, washed with 2%
uranyl acetate, blotted, stained with 2% uranyl acetate (1 min), then blotted dry. Grids were
viewed with a TECNAI G2 20 electron microscope (FEI Company, Hillsboro, OR) and digital
images were captured with the Gatan Digital Micrograph imaging system.
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The microtubule binding assay was performed in general tubulin buffer (80 mM PIPES, pH 7,
1 mM MgCl2, 1 mM EGTA). Tau protein ranging from 0.125 μM to 10 μM were mixed with
paclitaxel stabilized microtubules at a final concentration of 1.62 μM tubulin dimer in a 50
μL reaction. Samples were incubated at room temperature for 30 min, and centrifuged in a
Beckman Optima TLX ultracentrifuge at 100,000 × g for 5 min to sediment the microtubules
and tau bound to the microtubules. The pellets were resuspended in SDS sample buffer and
microtubules were separated from tau bound to microtubules by SDS-PAGE. The
concentration of tau bound to the microtubules was determined by the intensity of tau band by
Adobe Photoshop and normalized to the intensity of tubulin band. The tau band was normalized
to the intensity of the tubulin bands in each lane to account for any differences in centrifugation
or resuspension of samples because the amount of tubulin should be constant in all binding
reactions. The amount of free tau was determined by subtracting the amount of bound tau from
the total amount of tau. The concentration of bound tau were plotted versus the concentration
of free tau in GraphPad Prism and fit to a one site binding (hyperbola) equation.
Results
Selection and generation of pseudo-phosphorylation mutants
Hyperphosphorylated tau in Alzheimer’s disease (AD) is phosphorylated at a molar ratio of
approximately 5–9 mol phosphate per mol of tau whereas normal tau contains only 2–3 mol
phosphate per mol of tau (36). However, the role of this hyperphosphorylation is poorly
understood. To better understand the effects of tau hyperphosphorylation, pseudo-
phosphorylation mutants were constructed. We chose to focus on the five sites known to be
phosphorylated by GSK-3β in vitro when arachidonic acid-induced tau filaments are used as
the substrate (S199, T205, T231, S396 and S404) (20). Pseudo-phosphorylation changes at
S202 were added to generate the 6-phos, and both S202 and S235 were added to generate 7-
phos (Figure 1A). These sites were included since S202 is often found phosphorylated along
with S199, and S235 is often found phosphorylated along with T231. Single, paired and triplet
mutants were investigated to determine whether fewer sites might also have an effect on the
function of tau (Figure 1A). We also investigated a GSK-3β site in the same proline rich region
but not among the sites above (T212) as a control. As further controls, non-proline directed
sites S208, S210 and S208/S210 were investigated. The disease causing P301L tau mutation
was included in the analyses as a positive control.
Pseudo-phosphorylation at S199/S202/T205, S396/S404, 6-Phos and 7-Phos induces AD-like
changes in electrophoretic mobility
Alzheimer’s disease hyperphosphorylated tau and recombinant tau phosphorylated by
GSK-3β in vitro have an upward band shift when analyzed by SDS-PAGE (19,37). This upward
band shift is the definitive characteristic of hyperphosphorylated tau in neurodegenerative
disorders (1). To determine whether the pseudo-phosphorylation mutants can cause this upward
band shift, the pseudo-phosphorylation forms of tau were analyzed by coomassie-stained SDS-
PAGE electrophoresis. S199/S202/T205E, S396/S404E, 6-Phos and 7-Phos had an upward
shift in mobility compared to wild-type tau (Figure 1B). The apparent molecular masses for
wild-type, S199/S202/T205E, S396/S404E, 6-Phos and 7-Phos were 70 kDa, 72 kDa, 75 kDa,
78 kDa and 78 kDa, respectively. P301L tau and all other pseudo-phosphorylation mutants did
not show a change in mobility (data not shown). The mobility shift of pseudo-phosphorylation
mutants was reduced in the presence of 6M urea (molecular weights for wild-type, S199/S202/
T205E, S396/S404E, 6-Phos and 7-Phos were 70 kDa, 70 kDa, 71 kDa, 72 kDa and 72 kDa,
respectively, Figure 1C). This phenomenon of altered mobility in SDS that is abolished in urea
has been described in the literature as a SDS-resistant change in conformation (33,38–41).
Because S199/S202/T205E, S396/S404E, 6-Phos and 7-Phos all demonstrated an AD-like shift
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in mobility as a result of phosphorylation-like changes, we conclude that they have the
characteristics of hyperphosphorylated tau. These mutants will therefore be referred to as
pseudo-hyperphosphorylated tau throughout the manuscript.
Pseudo-phosphorylation of tau changes its affinity for microtubules
Because FTDP-17 mutations (42) and pseudo-phosphorylation mutations (28) in tau can alter
its interactions with microtubules, we measured the microtubule binding affinity of P301L tau
and fifteen pseudo-phosphorylation mutants using a centrifugation assay (43). Pellets
containing microtubules and bound tau were resuspended in SDS-sample buffer and analyzed
by coomassie-stained SDS-PAGE (Figure 2A). The concentration of tau bound to the
microtubules was determined by the intensity of tau band and normalized to the intensity of
tubulin band (Figure 2A). Normalization of the amount of tau relative to tubulin was performed
to take into account any differences in sedimentation or resuspension of the pellets. The
concentration of free tau was calculated by subtracting the measured bound tau from the total
tau added to the reaction. The amount of bound tau was plotted against free tau. Two
representative curves (wild-type tau and 7-Phos) are shown in Figure 2B. The data were fit to
a simple one-site binding equation to determine the affinity of binding (Kd) and the maximal
amount of bound tau (Bmax) (Figure 2C and 2D). All proteins examined, with the exception of
S199E, S202E and S208D, had significantly lower affinities for microtubules than was
observed with wild-type tau (Figure 2B). The decreases in binding affinity were all in the 2–
3 fold reduction range, which is in general agreement with previously published reports of
GSK-3β phosphorylation of tau (44) and the P301L mutation (42). The stoichiometry of
binding to microtubules was not greatly affected (Figure 2C).
Pseudo-phosphorylation influences the arachidonic acid induction of tau polymerization
To determine whether pseudo-phosphorylation mutations of tau have an effect on the
arachidonic acid (ARA) induction of tau polymerization, each protein at a final concentration
of 2 μM was incubated in the presence of 75 μM ARA. This protein to inducer ratio was chosen
since it has been shown to be the optimal condition for the arachidonic acid induction of wild-
type tau polymerization (34). The kinetics of polymerization of each mutant were followed by
right angle laser light scattering and compared to wild-type tau. Representative curves are
shown in Figure 3A. The data were fit to a Gompertz function to determine the maximal amount
of light scattering (LLSmax) (Figure 3B), the apparent proportional growth rate (kapp,Figure
3C), and the lag time of polymerization (Figure 3D). No significant increases in polymerization
were observed for the pseudo-phosphorylation mutants (Figure 3B), although the FTDP-17
mutation P301L did have a significant increase in the extent of polymerization compared to
wild-type, as expected (45). Several pseudo-phosphorylation variants (S202/T205E, S199/
S202/T205E, S208/S210D, T231E, S396/S404E, 6-Phos and 7-Phos) had significantly less
maximal polymerization as compared to wild-type.
The apparent proportional growth rate, kapp, was not significantly altered for most of the
mutants (Figure 3C). The FTDP-17 mutation P301L has been shown to have the most dramatic
effects in increasing the apparent rate of polymerization as compared to wild-type tau protein
(45), and had a significantly greater kapp than wild-type tau and all the pseudo-phosphorylation
mutants. Mutants S210D and T231D also had significantly greater kapp values than wild type,
but still less than P301L tau (Figure 3C). S199/S202/T205E, 6-phos and 7-phos all had
significantly lower kapp than wild type tau (Figure 3C).
Nucleation-elongation polymerization pathways are also typically characterized by a lag time
in the polymerization process. Wild type tau had a lag time of 19 minutes (Figure 3D). P301L
tau had a significantly reduced lag time, as expected (45). S210D, S208/S210D, T231E and
T231E/S235D also had significantly reduced lag times, but greater than P301L tau (Figure
Sun and Gamblin Page 5













3D). 6-phos had a significantly longer lag time than wild type tau (Figure 3D). On average,
S199/S202/T205E and 7-Phos had longer lag times than wild type, but these differences did
not reach statistical significance (Figure 3D).
Pseudo-phosphorylation changes the morphology of ARA-induced tau filaments
To determine whether filament morphology (number and length of filaments) was changed by
pseudo-phosphorylation, samples from polymerization reactions were prepared and viewed by
TEM (Figure 4). Filaments from six fields of view were combined into a single data set and
then ranked according to their length (examples are shown Figure 5A). Particles less than 15nm
in their longest dimension were not included in the analysis because particles smaller than this
cutoff value are smaller than the average filament width of arachidonic acid induced filaments
(19), and therefore difficult to distinguish from background. In general, pseudo-
phosphorylation mutants tended to form fewer but longer filaments than wild-type tau (Figure
5B and 5C). The standard deviation of the average lengths was roughly equal to the value of
the average lengths for most proteins, as is expected for exponentially distributed data (46).
The standard error of the mean is also shown, as this is an estimate of the accuracy of the
determination of the true mean. Among these mutants, the three with the most phosphorylation
sites formed the longest filaments (S199/S202/T20E5, 6-Phos and 7-Phos) (Figure 5C).
However, the overall amount of filament formation observed in six fields was relatively similar
for most all proteins (Figure 5D), with the possible exceptions of T231E, S202/T205E, T205E
and S396/404E which seemed to have somewhat reduced levels of polymerization compared
to the other proteins (Figure 5D). In general, pseudo-phosphorylation of tau resulted in fewer,
but longer filaments as compared to wild-type (Figure 4 and 5). In contrast, the rapidly
polymerizing P301L formed more, but shorter filaments than wild-type tau, resulting in an
overall increase in the amount of polymerized material (Figure 5A–D).
Quantitative analysis of differences between the filaments is difficult due to the differences in
the number of filaments, the variability in filament distribution on the TEM grid, the biological
variability in filament lengths, and the exponential distribution of filament lengths. Therefore,
it is possible that the apparent differences in filament length distributions (Figure 5) could be
due to differences in sampling. We therefore measured 500 filaments for each mutant and
determined the number-average length (Ln=(ΣNiLi)/(ΣNi), Figure 6) for each mutant (47). With
the exception of T231, all pseudo-phosphorylation mutants had greater average filament
lengths than wild type protein. This analysis also confirmed that S199/S202/T205E, 6-Phos
and 7-Phos had the greatest tendencies for forming long filaments.
Discussion
Significance of pseudo-phosphorylation mutants sites
Hyperphosphorylation of the microtubule-associated protein tau is a pathological hallmark of
Alzheimer’s disease and other tauopathies. Many kinases have been shown to be involved in
this phosphorylation process, and GSK-3β is believed to be a major contributor to tau/PHF
phosphorylation (reviewed in (11)). In previous studies, we found that GSK-3β
phosphorylation of pre-formed tau filaments at sites including S199, T205, T231, S396 and
S404 can cause tau filaments to coalesce into NFT-like structures (20). Because these five sites
are recognized by specific AD-associated antibodies, we sought to test whether pseudo-
phosphorylation at these sites would have an impact on the function of tau (summarized in
Table 1).
Role of phosphorylation in tau polymerization
Phosphorylation of tau at specific sites has been suggested to correlate with the formation of
neurofibrillary tangles (NFTs), raising the possibility that a major function of tau
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phosphorylation is to promote tau polymerization (48). Under conditions that we have
determined to be optimal for wild-type tau polymerization (34), pseudo-phosphorylation of tau
mildly reduced its polymerization, which is consistent with previously published reports using
in vitro GSK-3β phosphorylated tau (19,49). The kinetics of polymerization for most of the
single and double phosphorylation variants were not significantly changed (Table 1). However,
the pseudo-hyperphosphorylated version of tau (S199/S202/T205E, 6-Phos and 7-Phos) had a
drastically decreased rate of elongation and a pronounced lag time. This suggests a deficiency
in the nucleation step for the pseudo-hyperphosphorylation mimics. The observation of fewer
but longer filaments with pseudo-hyperphosphorylation mutants agree with this idea.
The effect on filament nucleation and filament length was greatest with the “pseudo-
hyperphosphorylated” versions of tau. 6-phos and 7-phos were generated from the combination
of multiple pseudo-phosphorylation sites in both the proline-rich and C-terminal regions of
tau. The effects on polymerization of 6-phos and 7-phos seem to be greater than those observed
by the heparin (49) or arachidonic acid (19) induction of GSK-3β phosphorylated tau
polymerization. However, GSK-3β phosphorylation in vitro only results in 2–4 mol phosphate
incorporation per mol of tau distributed unequally over as many as fourteen sites (19,20,49–
51). 6-phos and 7-phos are homogeneous in their modifications and therefore are more highly
modified than the average GSK-3β phosphorylated tau protein.
Our previous studies have shown that the presence of arachidonic acid drastically reduces the
energetic barrier for the nucleation of polymerization (34). The observation that pseudo-
hyperphosphorylation mutants are less likely to nucleate could be explained by diminished
interactions with arachidonic acid as a result of altered conformations of the proteins conferred
by pseudo-phosphorylation. In support of this, the pseudo-hyperphosphorylated proteins had
altered SDS-PAGE electrophoretic mobility that was abolished in the presence of urea. This
phenomenon has been described as an SDS-resistant change in conformation of tau (33,38–
41), and indicates that pseudo-phosphorylated proteins could interact differently with SDS or
with arachidonic acid.
It should be mentioned that a previous report found that pseudo-phosphorylation of tau at
several sites (including S199, S199/S202/T205 and T212) enhanced polymerization by 2–3
fold over non-modified tau (26). We obtain similar results when using concentrations of
arachidonic acid that inhibit wild type tau polymerization (125–150 μM, data not shown). It is
not clear whether these results at high inducer to protein ratios have physiological relevance,
but they are consistent with the hypothesis that pseudo-phosphorylation of tau can decrease its
interactions with arachidonic acid.
Role of phosphorylation in microtubule binding
Most pseudo-phosphorylation forms of tau significantly decreased microtubule binding by 2–
3 fold without significantly changing the saturation levels (Table 1), which agrees with previous
studies investigating the effects of tau phosphorylation at proline-directed phosphorylation
sites (49). However, results from multiple site constructs were not consistently additive. For
example, both T231E and S235D had lower affinities than wild-type for microtubules.
However, the T231E/S235D double mutant had an affinity similar to the individual mutations.
And while S202/T205E had a lower affinity for microtubules than the individual mutants, the
addition of S199E to form S199/S202/T205E actually improved microtubule binding (albeit
at a lower affinity than wild-type tau). The constructs with six or seven pseudo-phosphorylation
sites did not show dramatically different levels of microtubule binding than single or double
mutants. We conclude that microtubule binding is regulated in a complicated site-specific
fashion, and the levels of phosphorylation are less of a determinant of microtubule binding
than the actual sites involved.
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Phosphorylation, polymerization, NFTs and toxicity
Since the establishment of the correlation between the number of NFTs with the degree of
dementia in AD, NFTs have been widely accepted as a toxic species in AD (reviewed in
(52)). However, recent observations in tau-expressing cultured cell, transgenic Drosophila and
mouse models suggest that the toxicity is independent of NFT formation and NFTs may form
as a result of cellular attempts to reduce toxicity (reviewed in (53)). NFTs contain large amounts
of abnormal hyperphosphorylated tau (6) in the form of straight and paired-helical filaments
(4,5). The abnormal hyperphosphorylation of tau is one of the post-translational modifications
of tau known to be related to toxicity, filament formation and the formation of NFTs (reviewed
in (54)). The apparent phosphorylation-dependent toxicity of tau could be due to the disruption
of microtubule dynamics through sequestration of normal tau (55–57), and could be reduced
through the polymerization of phosphorylated tau (58). Additionally, the presence of soluble
hyperphosphorylated tau is correlated with cognitive deficiencies in a transgenic mouse model
(59). These results suggest that tau aggregation could protect against phosphorylation-induced
microtubule disruption and subsequent neurodegeneration.
Our results provide a potential biochemical mechanism for the potential cytotoxicity of
hyperphosphorylated tau. Phosphorylated tau binds to microtubules less tightly, so that there
would be an increase in cytoplasmic tau and increased microtubule instability. It has also been
shown through other work that hyperphosphorylated tau may sequester normal tau (56), further
disrupting microtubule dynamics. Pseudo-hyperphosphorylated tau also has a decreased rate
of polymerization, potentially increasing the amount of time it is soluble in the cytoplasm where
it could sequester normal tau. It is also possible that the fibrillization of abnormally
phosphorylated tau could protect cells from toxic effects. We have previously shown tau
phosphorylation by GSK-3β is sufficient to induce the bundling tau filaments into NFT-like
structures in a cell-free in vitro system (20). These observations are consistent with data from
transgenic mouse models showing that NFT formation is not necessarily the toxic element of
neurodegeneration and may instead play a protective role (59–61).
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Figure 1. Simulation of phosphorylation by glutamate or aspartate replacement
A) Diagram of phosphorylation sites on full-length tau. Four microtubule binding repeats are
indicated by light gray (R1-R4) and exon 2, 3 and 10 are indicated by dark gray boxes.
Phosphorylation sites that have been mutated to glutamate or aspartate are indicated to the right
of the diagram showing their position. The FTDP-17 mutant, P301L, is also indicated. The
mutants with “hyperphosphorylation”-like changes are marked with an asterisk. B) SDS-
resistant upward band shifts were observed in the pseudo-phosphorylation mutants S199/S202/
T202E, S396/S404E, 6-Phos and 7-Phos. 1 μg tau protein samples (wild-type tau (WT), S199/
S202/T202E, S396/S404E, 6-Phos and 7-Phos) were fractionated by SDS-PAGE on a 15%
gradient gel. C) SDS-resistant upward band shifts shown by S199/S202/T202E, S396/S404E,
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6-Phos and 7-Phos were reduced in the presence of 6M urea. 1 μg tau protein samples (wild-
type tau (WT), S199/S202/T205E, S396/404E, 6-Phos and 7-Phos) were fractionated by SDS-
PAGE in a 15% gel made with 6M urea.
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Figure 2. Microtubule binding of pseudo-phosphorylation mutants
The microtubule binding affinities of wild-type and mutant tau were measured using a
centrifugal assay to separate bound and unbound tau. A) A representative SDS-PAGE gel after
centrifugation. The concentrations of standard tau in first five lanes are 0.06, 0.125, 0.25, 0.5
and 1 μg, respectively. Tau protein, concentration varying from 0 to 10 μM, was mixed with
microtubules at constant total MT concentration of 1.62 μM tubulin dimers. Bound tau was
separated from free tau by centrifugation and fractionated on the SDS-PAGE lane 6–15. B)
Two representative curves plotting the concentration of bound tau versus tau free in solution
(● wild-type tau, ○ 7-Phos tau). The amount of bound tau was determined by the intensity of
tau band on SDS-PAGE. The data were fit to a one site binding equation. Kd and n were
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determined for each of three independent repetitions of the binding curves for each protein and
shown in panels C and D, respectively. All data are presented as the average of three
independent determinations of Kd and n ± s.d. (n=3). Values that were significantly different
from wild-type values at P < 0.05 (*) and P < 0.01 (**) were determined by t test.
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Figure 3. Kinetics of ARA induction of tau polymerization
The kinetics of wild-type and mutant tau polymerization at 2 μM protein and 75 μM ARA
inducer were monitored by laser light scattering. A) Four representative averaged curves of
the amount of light scattering (LLS) at the times indicated are shown for ■ wild-type; ▲ S199/
S202/T205E, ▼ 7-Phos, and ◆ P301L. Each experimental data set was fit to a Gompertz
function. LLSmax, kapp and lag time were determined from the equation as described in
Materials and Methods and are shown in panels B, C and D respectively. All data are presented
as averaged values ± s.d. from the three independent data sets. Values that were significantly
different from wild-type values at P < 0.05 (*) and P < 0.01 (**) were determined by one-way
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ANOVA analysis of variance with Dunnett’s multiple comparison post-test using wild type as
the control column.
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Figure 4. TEM analysis of polymerization at final concentration of 2 μM tau protein and 75 μM
ARA inducer
The polymerization of wild-type and mutant tau at 2 μM protein and 75 μM ARA inducer were
viewed by TEM after 20 hr incubation at room temperature. Representative micrographs are
shown. A) wt, B) S199E, C) S202E, D) T205E, E) S202/T205E, F) S199/S202/T205E, G)
S208D, H) S210D, I) S208/S210D, J) T212E, K) T231E, L) S235D, M) T231E/S235D, N)
S396/S404E, O) 6-Phos, P) 7-Phos and Q) P301L. Scale bar in Q) represents 500 nm and is
applicable to all images.
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Figure 5. Filament distribution of polymerization at final concentration of 2 μM tau protein and
75 μM ARA inducer
The polymerization of wild-type and mutant tau at 2 μM protein and 75 μM ARA inducer were
viewed by TEM after 20 hr incubation at room temperature. Resulting filament lengths were
measured using Optimas image analysis software. Six 36 μm2 fields were analyzed for each
protein. A) The filament lengths were combined into a single data set and ranked from shortest
to longest. Each individual filament length was plotted against its corresponding rank for each
protein. Several examples are shown and are individually labeled on the graph. The
distributions for S210D, S208/S210D, T231E/S235D and S396/S404E were similar to that of
T205E. The distributions for S202/T205, S208D and S235D were similar to S202E. The
distributions for T212E and T231E were similar to S199E. B) The total number of filaments
observed in six 36 μm2 fields are shown in ranked order from least to greatest. Each bar is
individually labeled on the graph. C) The average length of the filaments observed in six 36
μm2 fields are shown in ranked order from least to greatest. Each bar is individually labeled
on the graph. Values are shown as averages ± s.d. (error bars above only) and ± s.e.m. (bars
above and below). D) The sum of all filament lengths from six 36 μm2 fields are shown in
ranked order from least to greatest. Each bar is individually labeled on the graph.
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Figure 6. Pseudo-phosphorylation mutants form longer filaments than wild type tau
Wild-type and mutant tau protein (2 μM) were incubated in polymerization buffer with 75
μM ARA for 20 hr. Resulting filament lengths for 500 filaments were measured using Optimas
image analysis software. The number-average length ± s.d. (error bars above) and ± s.e.m.
(error bars above and below) for each protein was ranked by their average length and are labeled
on the x-axis.
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